EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Small molecule glucagon release inhibitors with activity in human islets

Michael A Kalwat, Karina Rodrigues-Dos-Santos, Derk D Binns, Shuguang Wei, Anwu Zhou, Matthew R Evans, Bruce A Posner, Michael G Roth, Melanie H Cobb

Frontiers in Endocrinology · 2023

DOI: 10.3389/fendo.2023.1114799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Endocrinology, 2023. Verfasst von Michael A Kalwat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Diabetes Center of Excellence, Indiana Biosciences Research Institute, Indianapolis, IN, United States. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Islets of Langerhans, Glucagon-Secreting Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Juvenile Diabetes Research Foundation United States of America, Welch Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Type 1 diabetes (T1D) accounts for an estimated 5% of all diabetes in the United States, afflicting over 1.25 million individuals. Maintaining long-term blood glucose control is the major goal for individuals with T1D. In T1D, insulin-secreting pancreatic islet β-cells are destroyed by the immune system, but glucagon-secreting islet α-cells survive. These remaining α-cells no longer respond properly to fluctuating blood glucose concentrations. Dysregulated α-cell function contributes to hyper- and hypoglycemia which can lead to macrovascular and microvascular complications. To this end, we sought to discover small molecules that suppress α-cell function for their potential as preclinical candidate compounds. Prior high-throughput screening identified a set of glucagon-suppressing compounds using a rodent α-cell line model, but these compounds were not validated in human systems.

Results

Here, we dissociated and replated primary human islet cells and exposed them to 24 h treatment with this set of candidate glucagon-suppressing compounds. Glucagon accumulation in the medium was measured and we determined that compounds SW049164 and SW088799 exhibited significant activity. Candidate compounds were also counter-screened in our InsGLuc-MIN6 β-cell insulin secretion reporter assay. SW049164 and SW088799 had minimal impact on insulin release after a 24 h exposure. To further validate these hits, we treated intact human islets with a selection of the top candidates for 24 h. SW049164 and SW088799 significantly inhibited glucagon release into the medium without significantly altering whole islet glucagon or insulin content. In concentration-response curves SW088799 exhibited significant inhibition of glucagon release with an IC50 of 1.26 µM.

Conclusion

Given the set of tested candidates were all top hits from the primary screen in rodent α-cells, this suggests some conservation of mechanism of action between human and rodents, at least for SW088799. Future structure-activity relationship studies of SW088799 may aid in elucidating its protein target(s) or enable its use as a tool compound to suppress α-cell activity in vitro .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Islets of LangerhansGlucagon-Secreting CellsHumansAnimalsGlucagonInsulin

Stichwörter der Autor:innen

Type 1 diabetes (T1D)alpha cellchemical biologyglucagonhigh-throughput (HT) screening

Substanzen

GlucagonInsulin

Autor:innen und Institutionen

  • Lilly Diabetes Center of Excellence, Indiana Biosciences Research Institute, Indianapolis, IN, United States.
  • Indiana University School of Medicine, Center for Diabetes and Metabolic Diseases, Indianapolis, IN, United States.
  • Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
  • Department Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, United States.

Förderung

  • NIDDK NIH HHS
  • Juvenile Diabetes Research Foundation United States of America
  • Welch Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Kalwat, M. A., Rodrigues-Dos-Santos, K., Binns, D. D., Wei, S., Zhou, A., Evans, M. R., Posner, B. A., Roth, M. G., & Cobb, M. H. (2023). Small molecule glucagon release inhibitors with activity in human islets. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1114799

Vancouver

Kalwat MA, Rodrigues-Dos-Santos K, Binns DD, Wei S, Zhou A, Evans MR, et al. Small molecule glucagon release inhibitors with activity in human islets. Frontiers in Endocrinology. 2023. doi:10.3389/fendo.2023.1114799

BibTeX
@article{Kalwat2023,
  author = {Kalwat, Michael A and Rodrigues-Dos-Santos, Karina and Binns, Derk D and Wei, Shuguang and Zhou, Anwu and Evans, Matthew R and Posner, Bruce A and Roth, Michael G and Cobb, Melanie H},
  title = {Small molecule glucagon release inhibitors with activity in human islets},
  journal = {Frontiers in Endocrinology},
  year = {2023},
  doi = {10.3389/fendo.2023.1114799}
}
Kostenlos starten →